Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Amarin (AMRN) Vascepa Pricing Leak?
December 3, 2012 3:21 PM ESTAmarin Corp Plc (NASDAQ: AMRN) investors were buzzing earlier today after a website inadvertently posted prices for Vascepa that appeared to be relatively low compared to market expectations.
GoodRx was showing prices of $51 for 30 capsules of 1g Vascepa (see below), although... More
Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
November 29, 2012 7:58 AM ESTAmarin Corporation plc (Nasdaq: AMRN) previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November 2012.
Amarin now expects to make this decision in the first half of... More



